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Targeted oral delivery of GFP fused with a GM1 receptor binding protein (CTB) or human cell penetrating
peptide (PTD) or dendritic cell peptide (DCpep) was investigated. Presence of GFPþ intact plant cells
between villi of ileum conﬁrm their protection in the digestive system from acids/enzymes. Efﬁcient
delivery of GFP to gut-epithelial cells by PTD or CTB and to M cells by all these fusion tags conﬁrm uptake
of GFP in the small intestine. PTD fusion delivered GFP more efﬁciently to most tissues or organs than the
other two tags. GFP was efﬁciently delivered to the liver by all fusion tags, likely through the guteliver
axis. In confocal imaging studies of human cell lines using puriﬁed GFP fused with different tags, GFP
signal of DCpep-GFP was only detected within dendritic cells. PTD-GFP was only detected within kidney
or pancreatic cells but not in immune modulatory cells (macrophages, dendritic, T, B, or mast cells). In
contrast, CTB-GFP was detected in all tested cell types, conﬁrming ubiquitous presence of GM1 receptors.
Such low-cost oral delivery of protein drugs to sera, immune system or non-immune cells should
dramatically lower their cost by elimination of prohibitively expensive fermentation, protein puriﬁcation
cold storage/transportation and increase patient compliance.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Biopharmaceuticals produced in current systems are prohibi-
tively expensive and are not affordable for a large majority of the
global population. In the US, the average annual cost of protein
drugs is 25-fold higher than for small molecule drugs. The cost of
protein drugs ($140 billion in 2013) exceeds the GDP of >75% of
countries around the globe, making them unaffordable in these
countries [1]. One third of the global population earning <$2 per
day cannot afford any protein drugs. Although recombinant insulin
has been sold commercially for ﬁve decades, it is still not affordable
for a large majority of global population. This is because of their
production in prohibitively expensive fermenters, coupled with a
need for puriﬁcation, cold storage/transportation, sterile delivery,
and short shelf life. Oral delivery of protein drugs has been elusivecost oral delivery of protein
Ltd. This is an open access article ufor decades because of their degradation in the digestive system
and inability to cross the gut epithelium for delivery to target cells.
However, several recent studies have indirectly shown that
plant cell wall protects expressed protein drugs from acids and
enzymes in the stomach via bio-encapsulation [2,3]. Human
digestive enzymes are incapable of breaking down glycosidic bonds
in carbohydrates that make up plant cell wall. However, when
intact plant cells containing protein drugs reach the gut,
commensal microbes could digest plant cell wall and release pro-
tein drugs in the gut lumen. Bacteria inhabiting the human gut have
evolved to utilize complex carbohydrates in plant cell wall and are
capable of utilizing almost all plant glycans [4,5]. Fusion of the
cholera non-toxic B subunit (CTB) to green ﬂuorescent protein
(GFP) expressed in chloroplasts and bio-encapsulated in plant cells
was delivered across the gut epithelium through GM1 receptors,
and GFP was released into the circulatory system [6]. Fusion of CTB
to therapeutic proteins facilitates their effective oral delivery for
induction of oral tolerance [7e11] or functional proteins to the
circulation [12e14] or even across blood brain or retinal barriers
[15,16].
Foreign proteins can also be delivered into living cells by fusionnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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penetration properties that do not require speciﬁc receptors [17].
The peptide and protein transduction domains (PTDs) are small
cationic peptides containing 8e16 amino acids in length, and most
frequently function as transporter for delivery of macromolecules
[17]. PTDs carry molecules into cells by a receptor independent,
ﬂuid-phase macropinocytosis, which is a special form of endocy-
tosis. Although different PTDs show similar characteristics of
cellular uptake, they vary in their efﬁcacy for transporting protein
molecules into cells. The efﬁcacy for cellular uptake has been found
to correlate strongly with the number of basic amino acid residues.
Since PTDs have been shown to deliver biologically active proteins
in cultured mammalian cells and in animal model in vivo and
in vitro [18e20], the PTD fused protein delivery method should
have great therapeutic drug delivery potential.
T and B lymphocytes are major cellular components of the
adaptive immune response, but their activation and homeostasis
are controlled by dendritic cells. B cells can recognize native Ag
directly through B cell receptors on their surface and secrete anti-
bodies. However, T cells are only able to recognize peptides that are
displayed byMHC class I and II molecules on the surface of antigen-
presenting cells (APCs). Macrophage is one type of professional
APCs, having many important roles including removal of dead cells
and cell debris in chronic inﬂammation and initiating an immune
response [21,22]. Macrophages participate in the orchestration of
primary and secondary immune responses. Mast cells are involved
in generating the ﬁrst inﬂammatory response during infection,
which is important for initiating innate and adaptive immunity.
When activated, a mast cell rapidly releases its characteristic
granules and various hormonal mediators into the interstitium.
Therefore, mast cells play important roles in wound healing,
allergic disease, anaphylaxis and autoimmunity.
Dendritic cell is one of the most important immune modulatory
cells. Dendritic cells (DCs) play critical roles in innate immune
sensing of pathogens and subsequent initiation of adaptive im-
mune responses. DCs present antigen to CD8þ T cells via MHC I and
to CD4þ Tcells viaMHC II and provide crucial co-stimulatory signals
to drive cellular and humoral immune responses. Conversely, DCs
are also critical for the homeostasis of regulatory T cells (Treg),
extrathymic induction of Treg, and for immune tolerance induction
in transplantation and treatment of allergy or autoimmune disease.
The tissuemicroenvironment, activation signals, and subsets of DCs
are important parameters that determine whether antigen pre-
sentation by DCs result in immunity or tolerance [23e25]. There-
fore, targeted in vivo delivery of antigens to DCs may not only be
useful for inducing tumor-speciﬁc immune responses and establish
novel strategies for vaccine development, cancer immunotherapy,
but also for tolerance induction protocols [26e28]. For example, the
gut associated lymphatic tissues (GALT) provide the largest surface
area for antigen entry into the body and a very unique microenvi-
ronment with tolerogenic properties, including expression of the
immune suppressive cytokines IL-10 and TGF-b [29e31]. Gut
epithelial cells and CX1CR5þ macrophages sample antigens from
the gut lumen. In particular in the endothelium of Peyer's patches,
microfold cells (M cells) endocytose and phagocytose antigens to
channel these to DCs. CD11cþ DCs in the gut contain a high pro-
portion of CD103þ DC, which express TGF-b preferentially induce
Treg [32]. Recently, we demonstrated that oral tolerance induction
to coagulation factors in hemophilic mice upon delivery of bio-
encapsulated CTB-fusion antigens was associated with increased
CD103þ DC frequency, antigen uptake by CD103þ DC, and induction
of several subsets of Treg [9,10]. Also increased were plasmacytoid
DC, which also have important immune modulatory functions [33].
Recently, DC peptide (DCpep) has been developed as a ligand to
mucosal DCs [26]. This small peptide binds to a DC-speciﬁc receptorand facilitates transportation of macromolecules into DC. These
properties can be exploited to efﬁciently deliver various molecules
to DCs for antigen presentation, to block their maturation, or to
modulate their functions.
In this study, we investigate oral administration of plant cells
expressing GFP fused with different tags in chloroplasts and eval-
uate cellular targeting and their bio-distribution. Delivery of PTD,
DCpep, and CTB fusions across the gut epithelium utilizing distinct
pathways result in systemic delivery, bio-distribution, and, perhaps
most importantly, distinct patterns of uptake by non-immune or
immune modulatory cells. These peptides could be used to deliver
therapeutic proteins to sera, immune modulatory cells or speciﬁc
tissues.
2. Methods
2.1. Creation of transplastomic lines expressing different tagged GFP
fusion proteins
The transplastomic plants expressing CTB-GFP and PTD-GFP
were created as described in previous studies [6,34]. DC speciﬁc
peptide, identiﬁed from screening of the Ph.D. 12-mer phage
display library [26] was conjugated to the C-terminus of GFP and
cloned into chloroplast transformation vector. Transplastomic lines
expressing DCpep-GFP were created and homoplasmic lines were
conﬁrmed using Southern blot assay as described previously [35].
Expression of GFP tagged proteins was conﬁrmed by visualizing
green ﬂuorescence from the leaves of each line under UV
illumination.
2.2. Lyophilization
The harvested mature leaves were stored at 80 C prior to
freeze-drying using a lyophilizer (Genesis 35XL, VirTis SP Scientiﬁc)
under vacuum (400 mTorr) with gradual increase of chamber
temperature from40 C to 25 C for 3 days. The lyophilized leaves
were then ground in a coffee grinder (Hamilton Beach) at
maximum speed 3 times (10 s each). The powdered plant cells were
stored under air-tight and moisture-free conditions at room tem-
perature with silica gel.
2.3. Quantiﬁcation of GFP fusion proteins and GM1 binding assay
The densitometry assay for quantiﬁcation of GFP fusion proteins
and GM1 ELISA assay were carried out according to previous
methods [14] using a GFP standard (Vector laboratories MB-0752-
100) and mouse monoclonal anti-GFP antibody (EMD MILLIPORE
MAB3580). Non-denaturing Tris-tricine gel was used for identiﬁ-
cation of pentameric structure of CTB-GFP according to previous
methods [36].
2.4. Puriﬁcation of tag-fused GFP proteins
PTD-GFP and DCpep-GFP, were puriﬁed via an organic extrac-
tion/FPLC based method as described[37]. Approximately 200 mg
lyophilized plant cells were homogenized in 10 ml of plant
extraction buffer (100 mM NaCl, 10 mM EDTA, 200 mM Tris-Cl pH
8.0, 0.2% Triton X-100, 400 mM sucrose, 2% v/v PMSF, 1 protease
inhibitor tablet in 10 mL total volume). The homogenate was spun
down after sonication and the supernatant was collected. The su-
pernatant was transferred to a 50 ml tube and subjected to organic
extraction as performed previously [37]. The plant extract was
treated with saturated ammonium sulfate to a ﬁnal concentration
of 70%. Then 1/4th of the total extract volume of 100% ethanol was
added, mixed vigorously for 2 min and then spun down. The
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50mL tube. To the remaining aqueous phase,1/16th of total volume
of 100% ethanol was added, shaken vigorously for 2 min and then
spun down again. The organic phases from both the spins were
pooled together and 1/3rd of total volume of 5 M NaCl and 1/4th of
the resulting volume of n-butanol was added and shaken vigor-
ously for 2 min and spun down. The resulting organic extract layer
(lower phase) was collected and then desalted by running it
through a 7 kDa MWCO desalting column (Thermo Scientiﬁc zeba
spin column 89893). The organic extract was loaded onto the
desalting column and spun down as per the manufacturer's in-
structions. Then the desalted organic extract (approximately 5 mL
volume) was then loaded onto a FPLC column (LKB- FPLC puriﬁ-
cation system, Pharmacia; 48 mL column volume). During the pu-
riﬁcation process, the sample was washed with 3.5 column
volumes of Buffer A (10 mM Tris HCl, 10 mM EDTA and 291 g
ammonium sulfate set at pH 7.8) with 20% ammonium sulfate
saturation. The columnwas then subjected to a stepwise increase in
Buffer B (10 mM Tris HCl, 10 mM EDTA sulfate set at pH 7.8) to elute
the GFP fusion. The protein was detected by measurement of
absorbance at 280 nm, which corresponded to a single peak that
was plotted on a recorder. The fraction corresponding to the peak
was collected in a single tube having a total volume of 9 mL. The
puriﬁed fraction was then dialyzed in 2 L of 0.01 PBS thrice and
then lyophilized (Labconco lyophilizer). The lyophilized puriﬁed
GFP fusions were then quantiﬁed by western blot/densitometric
method.
For the puriﬁcation of CTB-GFP, lyophilized leaf materials
(400 mg) were resuspended in 20 mL of extraction buffer (50 mM
NaeP, pH 7.8; 300 mM NaCl; 0.1% Tween-20; 1 tb of EDTA-free
protease inhibitor cocktail). The suspension was sonicated and
then centrifuged at 10,000 rpm for 10 min at 4 C. The supernatant
was combined with 1mL of His60 Ni resin (Clonetech, 635657), and
puriﬁcation was performed according to manufacturer's
instructions.
2.5. Purity measurement and coomassie staining
Total protein of puriﬁed from each GFP tag fraction was quan-
tiﬁed using Bradford assay then densitometry assay was carried out
to quantify the amount of GFP fusion protein in the fractions as
described in Section 2.3. Then the purity was evaluated by calcu-
lating the amount of GFP fusion protein relative to the total amount
of protein determined by Bradford assay. A non-denaturing 10%
SDS-PAGE was also performed in order to check ﬂuorescence of
the GFP fused proteins.
2.6. Evaluation of GFP expression
GFP levels in sera and tissues were quantiﬁed using our in-
house GFP ELISA. As previously described [6,16], blood and tissue
samples were collected at 2 and 5 h after the last oral gavage and
sera were stored at 80 C. Tissues were homogenized in RIPA
buffer and supernatants were collected for GFP ELISA assay. Our in
house ELISA protocol was established and standards were cali-
brated based on a GFP ELISA kit (AKR121; Cell Biolab). Brieﬂy, 96-
well Maxisorp plates (Nunc) were coated with goat polyclonal
GFP antibody (2.5 mg/mL, Rockland) in coating buffer (pH 9.6)
overnight at 4 C. The plates were blocked in PBS with 3% BSA for
2 h at 37 C. Serial 2-fold dilutions of sera in PBS with 1% BSA were
added in duplicate and incubated overnight at 4 C. The plate was
then incubated with biotin-conjugated rabbit polyclonal anti-GFP
1:5000 (Rockland) overnight at 4 C, followed by addition of
1:2000 diluted streptavidin peroxidases (Rockland). After further
incubation for 1 h at 37 C, plates were washed and substratesolution was added and incubated for 10 min at room temperature.
The reaction was stopped by adding 100 mL of 2N sulfuric acid per
well, and absorbance was measured using an ELISA reader at
450 nm. The results are shown as average ± SEM.
2.7. Mice and oral delivery experiments
Eight-week-old female C57BL/6 mice (Jackson Laboratories, Bar
Harbor, MI) were randomly divided into four groups (n ¼ 6 per
group) and orally gavaged with lyophilized bioencapsulated CTB-
GFP, PTD-GFP or DCpep-GFP plant cells (20 mg/mouse/day) for 3
consecutive days. All lyophilized materials were suspended in
200 mL PBS. On the 3rd day, blood samples were collected 2 and 5 h
after the last oral gavage. At the 5 h time point, all mice were
sacriﬁced, and organs (liver, kidney, lung, brain, tibialis anterior
muscle) were harvested and stored at 80 C. A control group
(n ¼ 6) was fed with untransformed lyophilized plant cells. Mice
were housed in the animal facilities of University of Florida and
University of Pennsylvania under controlled humidity and tem-
perature conditions, and all experiments were performed in
accordancewith the guidelines of Institutional Animal Care and Use
Committees.
2.8. Immunoﬂuorescent staining
As previously described [8,16], C57BL/6 mice were orally fed
with GFP expressing plant cells twice at 2-h interval. Two hours
after last feeding, mice were sacriﬁced, and liver and intestines
were removed. Intestines were cut open longitudinally and washed
with PBS, then rolled up and ﬁxed overnight in 4% para-
formaldehyde at 4 C. Liver tissuewas ﬁxed similarly. Subsequently,
ﬁxed tissues were further incubated in 30% sucrose in PBS at 4 C
and embedded in OCT. Serial sections were cut to a thickness of
10 mm.
For analysis of GFP expression, sections were permeabilized
with 0.1% Triton X-100, and blocked with 5% donkey serum in PBS
for 30 min, followed by incubationwith rabbit anti-GFP antibody at
1:1000 (ab290, Abcam) overnight at 4 C. The sections were then
incubated for 30 min with Alexa Fluor 488 donkey anti-rabbit IgG
(Jackson ImmunoResearch) or with rhodamine-labeled Ulex euro-
paeus agglutinin (UEA-1; Vector Labs; 10 mg/mL) for 10 min before
being washed and mounted with or without DAPI (4, 6 diamidino-
2-phenylindole). Images were captured using a Nikon Eclipse 80i
ﬂuorescence microscope and Retiga 2000R digital camera
(QImaging) and analyzed with Nikon Elements software.
2.9. Uptake of puriﬁed tag-fused GFP proteins by human cell lines
To determine the uptake of three tags, CTB, PTD and DC peptide
in immune modulatory cells, mature dendritic cells, human T cells
(Jurkat cell), human B cells (BCBL1), macrophage cells (mØ), mast
cells and non-immune modulatory cells, human kidney cells
(293T), human pancreatic epithelioid carcinoma cells (PANC-1) and
human pancreatic ductal epithelial cells (HPDE), were cultured and
used for in vitro incubation with puriﬁed tag-fused proteins. Cells
(2  104) were incubated in 100 mL PBS supplemented with 1% FBS
and puriﬁed CTB (8.8 mg), PTD (13.5 mg) or DCpep (1.3 mg) fused
protein at 37 C for 1 h. After washing with PBS, cell pellets were
stained with 1:3000 diluted DAPI and ﬁxed with 2% para-
formaldehyde at room temperature for 10 min. Cells were then
sealed on the slides with cytoseal and examined by confocal mi-
croscopy. For live imaging, after incubation with puriﬁed GFP fused
proteins, dendritic cells were loaded on glass bottom microwell
dishes (MatTek), stained with DAPI and observed under confocal
microscope. For 293T, PANC-1 and macrophage cells, cells were
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lowed by incubationwith puriﬁed CTB-GFP, PTD-GFP or DCpep-GFP
(same as above) at 37 C for 1 h. After washing wells with PBS, cells
were stained with 1:3000 DAPI and ﬁxed with 2% para-
formaldehyde at RT for 10 min. For negative control groups, cells
were incubated with commercial GFP (2 mg) in PBS with 1% FBS or
had no treatment. After 1 h of incubation, cells were washed once
with PBS. Live cells were imaged using a confocal microscope.
To determine the uptake efﬁciency of puriﬁed GFP fusion pro-
teins in different human cell lines, the number of cells showing GFP
signals was counted and is represented as a percentage of the total
number of cells observed. A total of 15e20 images were recorded
for each cell line in three independent samples under a confocal
microscope at 100 magniﬁcation.
3. Results
3.1. Creation and characterization of transplastomic lines
In this study we utilize three distinct transmucosal carriers.
Interaction of CTB pentamer to GM1 receptor has beenwell studied
as shown in Fig. 1A. The penta-saccharide structure of GM1 re-
ceptor interacts with amino acids of CTB via hydrogen bonds [38].
In contrast, mechanisms of structures shown for PTD (Fig. 1A) or
DCpep (Fig. 1A) has not been fully investigated. Secondary struc-
tures of cell-penetrating peptides (CPP) have been studied by cir-
cular dichroism (CD). Such peptides interact with negatively
charged phospholipid vesicles leading to induction of secondary
structures. Small uni-lamellar vesicles (SUVs) are used in such
studies. However, the exact role of any secondary structure of CPPs
in relation to translocation process is difﬁcult to deﬁne. It has been
shown that CPPs change their structure from alpha helix to beta
sheets depending upon experimental conditions, even in simple
model systems. So, they are described as “chameleons” in changing
their structure, rapidly adapting to membrane environment [39].
Therefore, secondary structures were not investigated in our
studies but we used interactive threading assembly reﬁnement
program (I-TASSER) to predict computational 3-D structures [40].
In Fig. 1A, the representative models were chosen based on the
calculation of parameters such as conﬁdence score (C-score), high-
resolution models with root mean square deviation (RMSD) value,
and template modeling score (TM-score). For example, if the TM-
score, assessing topological similarity of ﬁrst I-TASSER model to
corresponding structure in Protein Data Bank (PDB) library, is
greater than 0.5, the predicted topology is correct [40]. From the
predicted model, TM-score of PTD was 0.60 ± 0.14 and that of
DCpep was 0.58 ± 0.14. In predicted structures, while PTD has he-
lical structure, DCpep shows a loop structure. As expected, there is
no similarity between the two peptides.
All three tags were fused to the green ﬂuorescent protein
(smGFP) to evaluate their efﬁciency and speciﬁcity. CTB was fused
with GFP at the N-terminus via furin cleavage site, Pro-Arg-Ala-
Arg-Arg [6]. Sixteen amino acids (RHIKIWFQNRRMKWKK)
derived from pancreatic and duodenal homeobox factor-1 (PDX-
1) [41] were fused at the N-terminus with GFP and the fusion
protein is referred to as PTD-GFP in this study. For nuclear tar-
geting, additional localization signals are required. Six amino
acids (RH, RR, and KK) of the 16 aa-PTD are critical for nuclear
localization of PDX-1 [42]. Human dendritic cell speciﬁc peptide
ligand (FYPSYHSTPQRP) identiﬁed from screening of 12-mer
phage display library [26] was fused to the C-terminus of GFP.
Both PTD and DC-Peptide were engineered without the furin
cleavage site to study entry as well as tissue distribution. All these
three fusion constructs were cloned into the chloroplast trans-
formation vectors (pLD) which were used to transformchloroplasts as described in the material methods section.
To create plants expressing GFP fusion proteins, tobacco chlo-
roplasts were transformed using biolistic particle delivery system.
As seen in Fig. 1B, each tag-fused GFP is driven by identical regu-
latory sequences - the psbA promoter and 50 UTR regulated by light
and the transcribed mRNAs are stabilized by 30 psbA UTR. The psbA
gene is the most highly expressed chloroplast gene and therefore
psbA regulatory sequences are used for transgene expression in
our lab [7,35]. To facilitate the integration of the expression
cassette into chloroplast genome, two ﬂanking sequences,
isoleucyl-tRNA synthetase (trnI) and alanyl-tRNA synthetase (trnA)
genes, ﬂank the expression cassette, which are identical to the
native chloroplast genome sequence. The emerging shoots from
selection medium were investigated for speciﬁc integration of the
transgene cassette at the trnI and trnA spacer region and then
transformation of all chloroplast genomes in each plant cell
(absence of untransformed wild type chloroplast genomes) by
Southern blot analysis with the Dig-labeled probe containing the
trnI and trnA ﬂanking sequences (Fig. 1C). As seen in Fig. 1C, Hin-
dIII-digested gDNAs from three lines of each GFP plant showed
transformed large DNA fragments at 7.06, 6.79 and 6.78 kbp, for
CTB-GFP, PTD-GFP and DCpep-GFP, respectively, when hybridized
with the probe and absence of the untransformed smaller frag-
ment (4.37 kbp). Thus, stable integration of three different GFP
expression cassettes and homoplasmy of chloroplast genome with
transgenes were conﬁrmed. In addition, by visualizing the green
ﬂuorescence under UV light, GFP expression was phenotypically
monitored (Fig. 1D).
To scale up the biomass of each GFP tagged plant, each homo-
plasmic line was grown in a temperature- and humidity-controlled
automated Daniell lab greenhouse. Fully grownmature leaves were
harvested in late evenings to maximize the accumulation of GFP
fusion proteins driven by light-regulated promoter sequences. To
further increase the content of the fusion proteins on a dry weight
basis, frozen leaves were freeze-dried at 40 C under vacuum. In
addition to the concentration effect of proteins, lyophilization
increased shelf life of therapeutic proteins expressed in plantsmore
than one year at room temperature [13]. Therefore, in this study,
lyophilized and powdered plant cells expressing GFP-fused tag
proteins were used for oral delivery to mice. Immunoblot assay for
the GFP fused tag proteins showed identical size proteins in fresh
and 4-month old lyophilized leaves (Fig. 1E), conﬁrming stability of
fusion proteins during lyophilization and prolonged storage at
room temperature. In the immunoblot image, in addition to
monomers of 39.5 kDa, 29.2 kDa, and 28.3 kDa for CTB-GFP, PTD-
GFP, and DCpep-GFP, respectively, dimers were also detected for
PTD-GFP (58.4 kDa) and DCpep-GFP (56.6 kDa) (Fig. 1E). Homo-
dimerization is one of GFP physio-chemical features, which occurs
in solution and in crystals. The contacts between themonomers are
very tight due to extensive interactions which are composed of a
core of hydrophobic side chains from each monomer and a number
of hydrophilic contacts [43]. Also, CTB monomer can be self-
assembled to pentameric structure which is very stable and resis-
tant heat and denaturants due to the intersubunit interactions
within pentameric structure, which is mediated by hydrogen
bonds, salt bridges and hydrophobic interactions [44].
GFP protein concentration in powdered lyophilized leaf mate-
rials was 5.6 mg/mg, 24.1 mg/mg and 2.16 mg/mg for CTB-GFP, PTD-
GFP, and DCpep-GFP, respectively (Fig. 1C). GFP protein concen-
tration after lyophilization increased 17.1-, 12.7-, and 18.8-fold for
CTB-GFP, PTD-GFP, and DCpep-GFP, respectively (Fig. 1F). Removal
of water from fresh leaves by lyophilization is attributed to the
reduction of weight by 90e95%. This effect is then manifested as
10e20 fold increase of protein per gram of dry leaves [13,15,45].
Fig. 1. Schematic diagrams for predicted protein structures and characterization of transplastomic lines expressing GFP-fusion proteins. (A) Interaction of CTB fusion protein and
GM1 receptor, and predicted 3D structure of both PTD and DCpep. Pentasaccharide moiety of GM1 receptor establishes interaction with pentameric structure of CTB. The inlet box
shows atoms involved in the interaction between CTB and sugars in more detail [38]. The Hinge sequence for avoiding steric hindrance and furin cleavage site for releasing the
tethered protein were placed between CTB and the fused protein. Computational predicted three-dimensional structures of both PTD and DCpep were obtained from iterative
threading assembly reﬁnement (I-TASSER) server [40]. The structure is shown in rainbow, where the color changes from blue to red gradually for residues from N-terminal to C-
terminal (blue-green-yellow-orange-red). Among predicted structures, the model with the highest reliable structure for each peptide, which was chosen based on the combined
results from parameter calculations such as conﬁdence score (C-score), high-resolution models with root mean square deviation (RMSD) value, and template modeling score (TM-
score), was presented. (B) Schematic diagram for expression cassette of GFP-fused carrier proteins and ﬂanking regions. Prrn, rRNA operon promoter; aadA, aminoglycoside 30-
adenylytransferase gene; PpsbA, promoter and 50 UTR of psbA gene; CTB, coding sequence of cholera non-toxic B subunit; PTD, coding sequence of protein transduction domain;
DCpep, dendritic cell binding peptide sequence; smGFP, gene sequence for soluble-modiﬁed green ﬂuorescent protein; TpsbA, 30 UTR of psbA gene; trnI, isoleucyl-tRNA; trnA, alanyl-
tRNA. Restriction enzymes used for Southern blot analysis were indicated as BamHI/BglII for the generation of probe and HindIII for the digestion of genomic DNA. (C) Southern blot
analysis of each transplastomic line expressing GFP-fused tag proteins. HindIII-digested gDNAs were probed with the ﬂanking region fragment described above. (D) GFP ﬂuo-
rescence signals from each transplastomic line were conﬁrmed under UV light. The picture was taken after 2 months of germination. Bar represents 0.5 cm. (E) Western blot analysis
for densitometric quantiﬁcation with GFP standard proteins. Lyophilized (10 mg) and fresh leaf material (100 mg) were extracted in 300 mL extraction buffer. 1 represents 1 mL of
homogenate resuspended in the extraction buffer in a ratio of 100 mge300 mL. (F) Amount of GFP fusion proteins in fresh (F) and lyophilized (L) leaves. Data are means ± SD of three
independent experiments.
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For oral delivery, lyophilized plant cells (20 mg) were rehy-
drated in uniform volume (200 mL) and similar durations. Dispersed
plant cells do not vary in their size because mature plant cells are
uniform in size. As seen in Fig. 2, the bio-distribution of GFP does
not show any signiﬁcant variations. After oral delivery of lyophi-
lized plant cells expressing GFP (fused with PTD or CTB or DC
peptide), systemic GFP levels were higher in PTD-GFP fed animals
than any other tags tested (Fig. 2A). Biodistribution to liver and lung
was substantially higher than other tissues (skeletal muscle, kid-
ney). GFP levels in these tissues were consistently highest for PTD
fusion protein (Fig. 2B). Immunohistochemical studies using GFP-speciﬁc antibody offered further insight into the route of delivery.
As shown in Fig. 3A (3C insert), sensitive method of detection of
GFP using Alexa Flour 488 labeled secondary antibody revealed that
the PTD tag directed some GFP uptake by gut epithelial cells. No GFP
was detected when no primary antibody was used or when tissues
from mice fed with untransformed tobacco cells (Fig. 3B). In order
to more readily ﬁnd areas of gut where plant cells are located and
antigen uptake may be observed, the small intestine was rolled up
prior to ﬁxation, so that proximal and distal portions were visible
on the same slide (Fig. 3C). Presence of plant cells expressing GFP in
between villi of ileum (Fig. 3C and E) offers ﬁrst direct proof for
protection of plant cells from the digestive system. More wide-
spread delivery of GFP to epithelial cells was also seen when using
Fig. 2. Efﬁciency of oral delivery and biodistribution of GFP fused with different tags.
Serum (A) and tissue (B) GFP levels in mice (N ¼ 6 per group) fed leaf materials
expressing CTB-GFP, PTD-GFP and DCpep-GFP. Adult mice were orally fed with leaf
materials from transgenic tobacco plants, with the amount adjusted to GFP expression
levels, for three consecutive days. A control group (N ¼ 6) kept unfed. Blood samples
were collected at 2 and 5 h after last gavage at which, mice were sacriﬁced and tissue
samples were collected for protein isolation. GFP concentration in serum and tissues
were measured with ELISA. The data was shown as average ± SEM. Statistic signiﬁ-
cance was determined by a paired Student's t test, and p value less than 0.05 were
considered signiﬁcant. *P < 0.05, **P < 0.01, ***P < 0.05 or P < 0.01 (CTD, PTD and
DCpep versus Naïve).
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receptor by CTB pentamers. In addition to delivery to epithelial
cells, we also found evidence for uptake of GFP by M cells (solid
arrows in Fig. 3CeF) by all fusion tags. Again, these observations
provide direct evidence for uptake of proteins in the upper gut after
their lysis in the gut. Fig. 3E in particular illustrates the presence of
GFPþ plant cells (“PC”) of CTB-GFP transplastomic plants near the
site of delivery of released GFP to epithelial cells (“EC”) and M cells
(solid arrow) of the ileum. For DCpep-GFP, no GFPþ epithelial cells
were observed. However, we found examples of co-localization of
GFP and M cells (Fig. 3F), suggesting that systemic delivery of
DCpep-GFP is possible due to transport from the gut lumen via M
cells. GFP delivered with all three tags showed accumulation in the
liver (Fig. 3H, J and L), as expected because the blood can carry
antigens from the gut to the liver via the portal vein (“gut-liver-
axis”).3.3. Puriﬁcation of GFP fused with different tags
To study uptake of GFP by different cell types, the GFP fusion
proteins were puriﬁed using toyopearlbutyl column for PTD-GFP
and DCpep-GFP, and Ni2þ column for CTB-GFP. To examine the
purity, densitometry was done using western blots and GFP stan-
dard (Fig. 4A). The purity of each tag fused GFP was ~95% for PTD-
GFP, ~52% for DCpep-GFP, and ~13% for CTB-GFP. The variation in
purity levels is attributed to the differences in the expression levels
of each tag which is reﬂected on the recovered GFP fusion proteins
after puriﬁcation. Because proteins are puriﬁed based on hydro-
phobic interaction, other hydrophobic proteins could be present inthe puriﬁed fractions. The puriﬁcation of CTB-GFP was done with
afﬁnity Ni2þ column. Histidine cluster is generated when pen-
tameric structure of CTB is formed, then the imidazole rings in the
histidine cluster interact with Ni2þ [46]. The low purity of CTB-GFP
is due to less stringent wash step, but increasing the stringency was
accompanied with higher loss of the fused protein.
Puriﬁed GFP fusion proteins in SDS-PAGE and Coomassie stained
gels showed distinct bands for each fusion protein at expected
sizes, 29.2 kDa, 28.3 kDa and 39.5 kDa, for PTD-GFP, DCpep-GFP and
CTB-GFP, respectively, (Fig. 4B). In case of PTD-GFP, there are two
bands around at the expected size, which were 29.2 and 28.3 kDa. It
has been reported that the C-terminal tail (His-Gly-Met-Asp-Glu-
Tyr-Lys) of GFP is quite susceptible to proteolytic cleavage by car-
boxypeptidases and by nonspeciﬁc proteases including proteinase
K and pronase, and various isoforms, caused by partial proteolytic
cleavage, generated by ion exchange chromatography, isoelectric
focusing, and native gel electrophoresis [47]. In order to determine
GFP ﬂuorescence, non-denaturing SDS-PAGE was performed where
the ﬂuorescence intensity was strongest in PTD-GFP (Lane 1)
(Fig. 4C). In DCpep-GFP (Lane 2) 3 distinct proteins were seen with
the top band most likely representing dimerized GFP [47] and the
same was observed in PTD-GFP although it was of much higher
intensity. The CTB-GFP fusion showed a set of larger ﬂuorescence
bands (Lane 3) starting from 190 kDa which corresponds to the
pentamerization of CTB fused GFP and the other higher bands likely
representing multimers. At the same lane, a smaller fragment
slightly lower than the GFP standards was observed which could be
a differently folded product similar to what was observed in PTD-
GFP and DCpep-GFP.
To evaluate proper formation of pentameric structure of puriﬁed
CTB-GFP, GM1 binding assay was performed with anti-CTB and
anti-GFP antibody. It is well known that the pentameric structure of
CTB has strong binding afﬁnity to ganglioside GM1 receptors which
are found ubiquitously on the surface of mammalian cells [48]. As
seen in Fig. 4D, only CTB and CTB-GFP showed binding afﬁnity,
indicating complex formation between CTB and GM1. Also, the
interaction of GM1-CTB-GFP was reconﬁrmed using anti-GFP
antibody. Only CTB-GFP can be detected (Fig. 4E). To further
conﬁrm the pentameric structure of CTB-GFP, the puriﬁed CTB-GFP
was run on themodiﬁed Tris-tricine gels under the non-denaturing
conditions [36] and probed using anti-CTB antibody. The expected
pentameric CTB-GFP formwas detected at ~200 kDa along with the
monomeric form at 39.5 kDa (Fig. 4F). It is likely that the monomer
is dissociated from the oligomeric structure during the run due to
SDS, which was added in the gel and electrophoresis buffer.
Therefore, the CTB-GFP fusion protein formed the pentameric
structure and retained ability to bind to GM1 receptors, but there is
no GM1 binding afﬁnity for PTD-GFP or DCpep-GFP fusion protein.
3.4. Uptake of GFP fused with different tags by human immune and
non-immune cells
Puriﬁed GFP fusion proteins were incubated with human
cultured cells. Blood monocyte-derived mature DC, T cells (Jurkat
cell), B cells (BCBL1), differentiated macrophages and mast cells
were cultured for in vitro studies. Human kidney cells (HEK293T)
and human pancreatic epithelioid carcinoma cells (PANC-1) were
tested in parallel as examples of non-immune cells. Cells (2  104)
were incubated with puriﬁed CTB, PTD and DC target peptide fused
GFP for one hour at 37 C. Upon incubation with DCpep-GFP,
intracellular GFP signal was detected only in DCs and not for any
of the other cell type, conﬁrming its speciﬁcity (Fig. 5A). PTD-GFP
entered kidney cells or pancreatic cells but failed to enter any of
the immune modulatory cells (Fig. 5A). PTD sequence was derived
from PDX1 that induces insulin expression in pancreatic cells, and
Fig. 3. Visualization of GFP in cells of ileum and liver of mice after oral delivery of plant cells. GFP delivery to small intestine (left panel). Shown are cross-sections stained with anti-
GFP (green signal; Alexa Fluor 488), UEA-1 (which stains, among other cells, M cells, red signal, rhodamine), and DAPI (nuclear stain, blue). (AeC). PTD-GFP delivery. (B) No primary
antibody (NC: negative control). (DeE) CTB-GFP delivery. (F) DCpep delivery. Original magniﬁcation: 200 (A, B, D-F, insert in C) or 40 (C). GFP stain shown in liver's cryosection
(right panel), identical exposure time during image capture. The primary antibody: rabbit anti-GFP antibody at 1:1000 and secondary antibody: Alexa Fluor 488 Donkey Anti-Rabbit
IgG was used for GFP staining. (G, I and K) liver sections of mice fed with untransformed lyophilized plant cells. (H, J and L) GFP signals of liver sections from mice fed with
lyophilized plant cells expressing DCpep-GFP (H), PTD-GFP (J), and CTB-GFP (L). Original magniﬁcation: 100. Symbols and abbreviations: solid arrows: GFPþ M cells; open arrow:
GFP- M cell; EC: epithelial cells; PC: plant cells.
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and activated insulin gene [41]. As expected, strong GFP signal was
observed from PANC-1 cells when incubated with puriﬁed PTD-
GFP. Also, PTD-GFP was observed in nucleus of the pancreatic
ductal epithelial cells (Fig. 5B). The cell penetrating ability of PTD
was also evident in human kidney cell line (Fig. 5A). In sharp
contrast, GFP signals were detected in all cell types upon incubation
with CTB-GFP, consistent with ubiquitous presence of GM1 re-
ceptors (Fig. 5A). Bone marrow-derived murine mast cells (a cell
type that plays important roles in wound healing, defense to
pathogens, and allergic reactions) showed no internalization of GFP
delivered by DCpep or PTD, while CTB fused GFP was efﬁciently
taken up (Fig. 5A). Although only one representative image is
presented here, the uptake studies were performed in triplicates
and 15e20 images for each cell line were recorded under confocal
microscopy. CTB-GFP was observed in 70e92% of all the cell types
examined and the variations are due to differences in cell density
resulting in lower availability of GFP for their uptake. In case of
PTD-GFP, no uptake (0%) was observed in any other cell type except
kidney and pancreatic cells. DCpep-GFP was not observed in any
other cell type (0%) except in dendritic cells (Table 1). This study
offers speciﬁcity to deliver protein drugs to sera, immune system or
speciﬁc organs or tissues, thereby facilitating further advancement
of this novel concept.
4. Discussion
In our previous publications [6e16], we have shown that plant
cell-derived proteins fused with CTB can be delivered across the
intestinal epithelium for various applications, including delivery offunctional proteins to the circulatory system and of protein anti-
gens to the immune system (for oral tolerance induction or as a
booster vaccine). This is possible because of binding of CTB pen-
tamers to the GM1 receptors on the surface of gut epithelial and M
cells, followed by transcytosis. However, GM1 is widely expressed
by many different cell types and it is difﬁcult to target to speciﬁc
cell types. Therefore, in this study we sought to develop alternative
tags that result in either more cell type-speciﬁc and/or more efﬁ-
cient transmucosal delivery. We chose DCpep as an example for
speciﬁc delivery to professional antigen presenting cells and were
able to conﬁrm its speciﬁcity. PTD not only delivers the GFP cargo
more effectively to the circulation via penetration of intestinal
epithelial cells (Fig. 3A and C) but totally avoids delivery to immune
cells (Fig. 5A). In our opinion, data presented here on PTD are
paradigm shift in drug delivery, in sharp contrast to previous as-
sumptions that they are non-speciﬁc.
Given recent disagreements in the literature about mechanisms
of cell penetration by PTDs (macropinocytosis vs direct transfer)
and about effects of PTDs vs the cargo they carry [49], this is a very
timely contribution to this ﬁeld. Our data show that the body's
immune system can be excluded from protein drug delivery by
speciﬁc choice of PTD, while efﬁciently delivering to other cell types
and circulation. Thus, this study is likely to spark new in-
vestigations on screening of PTDs and determining their speciﬁcity.
Combined with sequence and structural knowledge, this will
hopefully lead to custom-designed PTDs in the future. We used
deﬁned in vitro systems to demonstrate the differences in protein
transduction between different tags as a function of the target cell
type. Future studies will focus on immunological consequences,
using disease-speciﬁc antigens instead of GFP and corresponding
Fig. 4. Characterization of puriﬁed GFP fused proteins. (A) Quantiﬁcation of puriﬁed GFP fused proteins, and coomassie staining and ﬂuorescence image. Densitometric assay with
western blot image was done with known amount of GFP standard protein to quantify the puriﬁed tag-fused GFP proteins. Puriﬁed proteins were run on SDS- PAGE and
immunoprobed with anti-GFP antibody. Loading amounts were indicated as shown. Purity was calculated as a percentage of the amount detected on the immunoblot assay to total
loading amount. (B) Coomassie staining of puriﬁed GFP tagged proteins. M, protein molecular weight marker; lane 1, PTD-GFP (10 mL, 2.37 mg); lane 2, Dcpep-GFP (40 mL, 3.12 mg),
lane 3, CTB-GFP (10 mL, 32.8 mg), and lane 4, GFP (400 ng). (C) Non-denaturing SDS-PAGE of puriﬁed GFP fusion proteins in order to determine GFP ﬂuorescence. Lane 1 (PTD-GFP
10 mL, 9.17 mg TSP loading), lane 2 (DCpep-GFP 15 mL, 4.6 mg TSP loading) and lane 3 (CTB-GFP 20 mL, 33 mg TSP loading). (D and E) The puriﬁed GFP-tagged proteins were examined
for their binding afﬁnity to GM1 receptor. Anti-CTB (D) and anti-GFP (E) antibody were used to detect the interaction between GM1 and the GFP fusion proteins. The protein
amounts used for the assay are as follows. CTB, 10 pg; CTB-GFP, 1.25 ng; PTD-GFP 10 ng; DCpep-GFP 10 ng; GFP, 10 ng and UT, untransformed wild type total proteins,100 ng. (F) Non-
denaturing Tris-tricine PAGE of puriﬁed CTB-GFP to determine pentameric structure. Pentameric structure of puriﬁed CTB-GFP was immunoprobed using anti-CTB antibody (1 in
10,000). Loading amounts of CTB-GFP are indicated as in the ﬁgure.
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To reveal routes by which the GFP fusion proteins cross the in-
testinal epithelial layer and delivery to circulation and bio-
distribution to other organs, the immunostaining studies of small
intestine tissue sections after oral delivery of leaf materials
expressing three GFP tag proteins were carried out. CTB was
conﬁrmed to be targeted to GM1 receptors on epithelial cells and
by M cells. Our study found that PTD is able to penetrate non-
immune cells, which explains why this tag also transfers GFP to
epithelial cells. In contrast, DC peptide is a speciﬁc ligand to den-
dritic cells and therefore should not target epithelial cells. However,
our data show that uptake by M cells is a mechanism of entry for
DCpep fusions, thus explaining how systemic delivery of DCpep-
GFP is possible via the oral route. Dendritic cells are also directly
targeted by DCpep through their protrusions between epithelial
cells. However, the amounts of gut luminal antigen sampled by this
mechanism are too small to be visualized.
We expect that protein antigens released from CTB after trans-
cytosis are taken up by DC (and to a lesser extent by macrophages)
in the gut immune system (as we have extensively published) and
that DCpep-GFP translocated by M cells is also taken up by DC.
However, for initial studies of interactions with immune cells, we
utilized a more sensitive and deﬁned in vitro approach usingcultured human cells. Future investigations will address antigen
uptake and processing in vivo and the resulting immune responses.4.1. Is CTB fusion ideal for oral immune modulatory therapy?
CTB fusion delivered GFP to all tested tissues and cell types
including non-immune and immune cells. It is well established that
CTB speciﬁcally binds with GM1 ganglioside and lots of CTB-fused
proteins expressed in chloroplasts in our lab also showed the
strong binding afﬁnity to GM1 [6,8,9,13e16]. CTB travels retrograde
through the trans-Golgi Network into the endoplasmic reticulum
(ER) for cell entry once CTB binds with GM1, enriched in membrane
lipid rafts of intestinal epithelial cells [50,51]. In fact, CTB has been
widely used as a probe to quantitatively study GM1 and its cellular
and subcellular distribution [52]. The use of CTB as a transmucosal
carrier can facilitate the transportation of conjugated proteins into
circulation through its strong binding afﬁnity to GM1 and the large
mucosal area of human intestine, approximately 1.8e2.7m2 against
body weight [53]. Up to 15,000 CTB molecules can bind to one in-
testinal epithelial cell at a time [54] and the GM1 receptor turns
over rapidly on the cell surface [55]. Furthermore, GM1 ganglio-
sides are also found in the plasma membranes of many other cell
types, with particular abundance in the nervous system and retina
Fig. 5. Uptake of GFP fused with different tags by human immune and non-immune
cells. (A) Translocation of puriﬁed GFP fusion proteins in human cell lines. 2  104
cells of cultured human dendritic cell (DC), B cell, T cell and mast cells were incubated
with puriﬁed GFP fusion: CTB-GFP (8.8 mg/100 mL PBS), PTD-GFP (13 mg/100 mL PBS),
DCpep-GFP (1.3 mg/100 mL PBS) and commercial standard GFP (2.0 mg/100 mL PBS)
respectively, at 37 C for 1 h. After PBS washing, B, T and mast cell pellets were stained
with 1:3000 diluted DAPI and ﬁxed with 2% paraformaldehyde. Then the cells were
sealed on slides and examined by confocal microscopy. Live DCs were stained with
1:3000 diluted Hoechst and directly detected under the confocal microscope. For 293T,
pancreatic cells (PANC-1 and HPDE) and macrophage cells, eight-well chamber slides
were used for cell culture at 37 C for overnight. After incubated with puriﬁed CTB-GFP
(8.8 mg/100 mL PBS), PTD-GFP (13 mg/100 mL PBS), DCpep-GFP (1.3 mg/100 mL PBS) and
commercial standard GFP (2.0 mg/100 mL PBS) respectively, at 37 C for 1 h, washed in
PBS and stained nuclei with 1:3000 DAPI. (B) Nuclear localization of PTD-GFP in hu-
man pancreatic ductal epithelial cells (HPDE). Green ﬂuorescence shows GFP expres-
sion; blue ﬂuorescence shows cell nuclei labeling with DAPI. The images were
observed at 100 magniﬁcation. Scale bar represent 10 mm. All images studies have
been analyzed in triplicate.
Table 1
Uptake efﬁciency of puriﬁed GFP fusion proteins in human cell lines. The relative
delivery efﬁciency of GFP to human cell lines by three different tags was compared
by counting the number of cells showing GFP signals under confocal microscope at
100magniﬁcation. A total of 15e20 images were observed for each cell line. All cell
lines were examined in triplicate.
CTB-GFP PTD-GFP DCpep-GFP
Human Dendritic cell 70.4% (19/27) 0% (0/12) 83% (10/12)
Human T cell 91.7% (11/12) 0% (0/18) 0% (0/13)
Human B cell 87.5% (14/16) 0% (0/14) 0% (0/10)
Human macrophage cell 91.7% (11/12) 0% (0/12) 0% (0/12)
Human mast cell 91.7% (11/12) 0% (0/12) 0% (0/11)
Human Kidney cell 83.3% (12/13) 83.3% (10/12) 0% (0/10)
Human pancreatic cells 89.5% (17/19) 81.2% (9/11) 0% (0/12)
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these cells.
Our strategy of oral tolerance induction to autoantigens and to
therapeutic proteins used in replacement therapy of genetic dis-
order (such as hemophilia and lysosomal storage disorders) has in
part relied on efﬁcient targeting of gut epithelial cells with CTB
followed by transmucosal delivery and proteolytic cleavage,
resulting in the release of the antigen from the CTB tag and uptake
by DCs [7,9e11,33]. However, DCs and macrophages also directly
sample antigen in the gut lumen, and M cells may shuttle intact
antigen across the epithelium to areas rich in DCs. Our new data
show that CTB fusions are efﬁciently taken up by DC, macrophages,
and other immune cells, providing an additional explanation for
the effectiveness of CTB fused antigens in plant-based immune
modulatory protocols.
We had also used CTB fusions effectively as oral booster vaccines
against pathogens after initial priming in the presence of aluminum
adjuvant [46]. However, when primed with adjuvant, CTB is highly
immunogenic and therefore diverts the speciﬁc response from
antigen of interest [46,58], limiting its use in vaccine development.
Aggregation of protein antigens due to formation of multimers or
pentamers and size restrictions of this transmucosal carrier are
additional potential limitations. Determination of antigen dose is
yet another major challenge because this would require complete
solubilization of CTB pentamers. Therefore, there is a need to
explore other pathways for oral delivery and investigate the point
of entry of protein antigens. Accurate targeting of therapeutic
proteins to a speciﬁc tissue minimizes side effects and increases
efﬁcacy, which eventually increases therapeutic beneﬁt to patients.
4.2. Speciﬁc targeting of dendritic cells by DCpep ideal for delivery
to the immune system
Here, we introduce an alternative and more speciﬁc peptide
sequence with high potential for immunotherapy. DCpep specif-
ically targets DCs but not any other immune cells or non-immune
cells. To assess translational implications, we mostly used human
immune cells to differentiate targeting characteristics of the fusion
tags. DCpep only delivered intact GFP antigen to DCs but not any
other APCs or immune cells or non-immune cells. Consistent with
this ﬁnding, DCpep-GFP failed to target gut epithelial cells in vivo.
Systemic delivery most likely resulted from uptake by M cells.
Going forward, one can now design immune tolerance and vaccine
protocols based on speciﬁc delivery to DC, which have critical
functions in Treg induction and immune stimulation, depending on
activation signals.
As we know, the delivery of antigens to lymph node is quite
important for immunotherapy. However, this aspect cannot be
directly demonstrated by GFP signal because proteins taken up by
DC in the lamina propria or Peyer's patches are fragmented into
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have migrated to the lymph nodes for presentation of antigen to T
cells. In agreement with the notion that mesenteric lymph nodes
(MLN) are critical in their response to ingested antigens, we
recently demonstrated increases in different DC subsets and in-
duction of Treg in the MLNs of mice that received oral delivery of
transplastomic plant cells [10].
4.3. PTD is ideal for efﬁcient systemic delivery via the oral route
excluding the immune system
While CTB fusions effectively target the gut immune system and
are thus useful for tolerance induction, an alternative strategy to
avoid immune complications is to minimize interactions with the
immune system. The protein transduction domain of PDX-1
exhibited unique selectivity in the transfer of GFP to different cell
types. PTD-GFP entirely failed to deliver antigen to APCs and lym-
phocytes but was able to transfer GFP to non-immune cells
(including gut epithelial cells in vivo). Since myeloid and lymphoid
cells are hematopoietic cells, it is possible that PDX-1 fails to
transduce this speciﬁc cell lineage. PDX-1 induces insulin expres-
sion upon protein transduction via macropinocytosis, a specialized
form of endocytosis that is distinct from receptor-mediated uptake
[59,60]. Macropinocytosis is also major mechanism of uptaking
macromolecules in kidney, so the observation of GFP signals in
HEK293T after incubation with puriﬁed PTD-GFP could be the
consequence of the endocytosis induce by PTD. Lack of GFP signal in
immune cells after incubation with PTD-GFP cannot be explained
by enhanced degradation after uptake but rather reﬂects a failure of
protein transduction of these cells because i) therewas also a lack of
binding to the cell surface, and ii) the PTD of HIV tat, which also
utilizes the macropinocytosis mechanism, readily delivers intact
GFP into human DC and other APCs by the PTD of HIV tat [61e63].
PTD derived from PDX-1 clearly displays a distinct selectivity for
cellular transduction, possibly related to surface properties of the
target cell membrane. Although both PTDs enter the cell by mac-
ropinocytosis, their amino acid sequences are very different, which
is likely to affect cell surface binding. While infection of lympho-
cytes is a critical step of the HIV life cycle, insulin expression needs
to be tightly regulated and responsive to environmental stimuli
[64], whichmay in part account for the selectivity of PTD from PDX-
1. At the same time, PTD-GFP was superior in vivo for systemic
protein delivery, which can be exploited for therapies that require
certain protein levels in the blood, such as in our published ex-
amples of treatment of hypertension and hormone or cytokine
therapies [9,11,14,15]. Interestingly, despite marked differences in
systemic delivery, CTB-, DCpep-, and PTD-tags all resulted in very
similar GFP antigen levels in the liver, as evidenced by immuno-
histochemistry and more quantitatively by ELISA. Links between
responses in the gut and the liver have long been known and are
often referred to as the “guteliver axis”. Upon uptake by the gut,
antigen can trafﬁc to the liver indirectly via migratory DC that is
routed through the mesenteric lymph node. Alternatively, the
blood can carry antigens from the gut to the liver via the portal vein.
Given the broad distribution of quantiﬁable levels of GFP in the
liver, the latter explanation seems more likely for our delivery
system. The data suggest that the liver takes up the orally delivered
antigen to a level of saturation that is less dependent on the tag.
4.4. Unique advantages of delivery of proteins bioencapsulated in
plant cells
Lyophilization of plant cells has several advantages. The freeze-
dried powdered leaves can be stored at room temperature for years
eliminating expensive cold storage and transportation which arerequired for injectable protein drugs [13,65]. Also, concentration
effect of the therapeutic protein is increased facilitating 10e20 fold
reduction in the size of capsules containing lyophilized plant cells.
Freeze drying technology is widely used to preserve protein drugs
by the pharmaceutical industry, including preservation of blood
clotting factors. So, freeze drying process doesn't denature proteins.
Indeed, we have repeatedly shown that freeze drying preserves
proper folding and disulﬁde bonds [11, 13e16, 66]. Upon oral de-
livery, lyophilized plant cells reach the intestine, and the bio-
encapsulated proteins are released by gut microbes through
digestion of plant cell wall. That time, the released proteins as well
as plant cell walls can be degraded by gut microbes. However, it is
possible that the gut microbiome is enriched by anaerobic bacteria
that release more enzymes to degrade plant cell wall than protein
degradation. Bacteria inhabiting the human gut have indeed
evolved to utilize complex carbohydrates in plant cell wall and are
capable of utilizing almost all plant glycans [4,5]. Our previously
published work identiﬁed enzymes that are required to breakdown
plant cell wall [67,68]. Delivery of several functional proteins show
that they are either protected in the gut lumen or adequate quan-
tities of protein drugs are released that survive gut lumen
proteases.
DCpep-GFP content was found to be the lowest among three
fusion proteins, 2.16 mg/mg, which is 10 times lower than that of
PTD-GFP. Generally, chloroplast expression of foreign protein can
reach very high level, up to 70% of total leaf proteins [7] due to high
copy number of chloroplast genome. However, expression level
varies based on protein, N-terminal fusions, proteolytic cleavage
and stability. In this study, all the chimeric genes were driven by the
psbA promoter and psbA 50UTR, and stabilized psbA 30UTR. Since the
GFP sequence is also same among all three constructs, the
contributing factors that affect the difference of the expression
level could be due to the N-terminal sequence of the fusion con-
structs. In contrast to PTD and CTB tag, DCpep was fused to C-ter-
minal of GFP. Therefore, one possible explanation for lower level of
GFP expression of DCpep fusion is inadequate protection of the N-
terminus.
5. Conclusions
As illustrated above, bioavailability of oral delivery of protein
drugs expressed in geneticallymodiﬁed plant cells is now emerging
as a new concept for inducing tolerance against autoimmune dis-
orders [7] or to eliminate toxicity of injected protein drugs [8e10]
or deliver functional blood proteins to treat diabetes [12,13], hy-
pertension [14], protection against retinopathy [15] or removal of
plaques in Alzheimer's brain [16]. These novel approaches should
improve patient compliance in addition to signiﬁcantly lowering
the cost of healthcare as seen in the diabetes study in which oral
delivery was as effective as injectable delivery to lower blood
glucose levels using insulin or exendin-4 [12,13].
This study has enabled utilization of different fusion tags to
deliver either to immune modulatory cells or non-immune cells or
directly to sera without interfering with the immune system. This
opens up the potential for low cost oral delivery of proteins to
enhance or suppress immunity or functional proteins to regulate
metabolic pathways.
The cost of protein drugs now exceeds GDP of >75% of countries,
making them unaffordable. This is because of their production in
prohibitively expensive fermenters, puriﬁcation, cold storage/
transportation, short shelf life and sterile delivery methods. Using
green ﬂuorescent protein (GFP) as a model, we demonstrate in this
study that plant cells protect GFP from the digestive system and
release it into the gut lumen where they are absorbed by epithelial
cells. Based on the delivery tag fused to GFP, they reach the
Y. Xiao et al. / Biomaterials 80 (2016) 68e7978circulatory system, immune cells or non-immune cells, speciﬁc
organs or tissues. Such low cost oral delivery of protein drugs
should increase patient compliance and dramatically lower their
cost by elimination of currently used prohibitively expensive pro-
cesses/injections.
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